Peter Traber
Directeur/Membre du Conseil chez Baylor College of Medicine
Fortune : 143 180 $ au 30/06/2024
Profil
Peter G.
Traber is currently the Chief Executive Officer at Baylor College of Medicine since 2003.
He previously held positions as Chairman & Chief Executive Officer at Terrasep LLC, Chairman-Internal Medicine Department at the University of Pennsylvania Medical Center, Director at Noble International Ltd., Director at Tanox, Inc., Independent Director at Caladrius Biosciences, Inc., President, Chief Executive & Medical Officer at Galectin Therapeutics, Inc. from 2017 to 2018, Chief Medical Officer at GSK Plc from 2000 to 2003, Chief Medical Officer at Morphic Therapeutic, Inc., Partner at Alacrita Consulting Ltd.
from 2018 to 2020, and Chief Medical Officer at Cartesian Therapeutics, Inc. He also served as the Chief Medical Officer at Selecta Biosciences, Inc. from 2020 to 2023.
Dr. Traber received his undergraduate degree from the University of Michigan and his doctorate from The Wayne State University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,03% | 18/04/2024 | 5 301 ( 0,03% ) | 143 180 $ | 30/06/2024 |
Postes actifs de Peter Traber
| Sociétés | Poste | Début |
|---|---|---|
| Baylor College of Medicine | Directeur/Membre du Conseil | 01/01/2008 |
Anciens postes connus de Peter Traber
| Sociétés | Poste | Fin |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 13/11/2023 |
| Alacrita Consulting Ltd. | Corporate Officer/Principal | 01/08/2020 |
| GALECTIN THERAPEUTICS INC. | Directeur Général | 06/07/2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Directeur/Membre du Conseil | 03/08/2007 |
Formation de Peter Traber
| University of Michigan | Undergraduate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 8 |
|---|---|
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Noble International Ltd.
 Noble International Ltd. Auto Parts: OEMProducer Manufacturing Noble International Ltd. manufactures and supplies automotive components, provides laser welding and cutting services. The company is headquartered in Troy, MI. | Producer Manufacturing |
| Terrasep LLC | |
The University of Pennsylvania Health System
 The University of Pennsylvania Health System Miscellaneous Commercial ServicesCommercial Services The University of Pennsylvania Health System provides general patient care as well as medical education and research services. The company was founded in 1874 and is headquartered in Philadelphia, PA. | Commercial Services |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
| Alacrita Consulting Ltd. | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
